Combination Therapy with Januvia and Rybelsus

Introduction to Combination Therapy

The American Diabetes Association recommends that GLP-1 receptor agonists should not be combined with DPP-4 inhibitors, as there is no added glucose-lowering benefit beyond that of the GLP-1 RA alone 1, 2

Rybelsus reduces HbA1c by 1-2% when added to metformin, while Januvia reduces HbA1c by only 0.5-0.8%, and adding Januvia to Rybelsus provides no meaningful additional glucose reduction 1
Combining these agents adds unnecessary medication cost without clinical benefit 2

In patients with impaired renal function, Rybelsus is strongly preferred over Januvia due to the need for dose adjustment with Januvia when eGFR falls below 45 mL/min/1.73 m² 1, 3
Semaglutide has demonstrated beneficial effects on cardiovascular disease, mortality, and kidney outcomes in patients with chronic kidney disease, while sitagliptin showed only cardiovascular safety without benefit 1
For patients with eGFR <30 mL/min/1.73 m², GLP-1 receptor agonists like semaglutide are preferred for glycemic management due to lower hypoglycemia risk and cardiovascular event reduction 4

If a patient is currently taking both medications, discontinue Januvia immediately and continue Rybelsus alone, as the GLP-1 RA provides superior glucose control and cardiovascular/renal benefits 1, 2
If the patient is already on Januvia with inadequate control, switch to Rybelsus rather than adding it to Januvia 2
If cost is a barrier to Rybelsus, continue Januvia alone, but recognize that for patients with established cardiovascular disease, heart failure, or chronic kidney disease, SGLT2 inhibitors or GLP-1 receptor agonists should be prioritized 4, 5, 1

Never combine incretin-based therapies, including GLP-1 receptor agonists with DPP-4 inhibitors or combining different agents within the same class 5, 1
For patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, Rybelsus is strongly preferred over Januvia due to proven cardiovascular and renal benefits 4, 5, 1